← Arcus Biosciences, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations — — — — — — ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Net Income (Loss) Attributable to Parent — ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Depreciation and amortization $1.3m $2.6m $3.7m $3.6m $3.1m $3.8m $6.0m $8.0m $10.0m $10.0m
Amortization of discounts on marketable securities $0 $0 ($1.8m) ($2.6m) ($46k) $4.8m $0 ($19.0m) ($25.0m) ($13.0m)
Amortization Of Securities — — — — — — $0 ($19.0m) ($25.0m) ($13.0m)
Depreciation Amortization Depletion — — — — — — $6.0m $8.0m $10.0m $10.0m
Share-based Payment Arrangement, Noncash Expense — $495k $3.9m $9.0m $21.8m $54.5m $65.0m $73.0m $76.0m $60.0m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — — $7.0m $0
Share-based Payment Arrangement, Expense — — — — — — $65.0m $73.0m $76.0m $60.0m
Operating Lease, Impairment Loss — — — — — — — — $20.0m $0
Impairment on right-of use assets — — — — — — $0 $0 $20.0m $0
Asset Impairment Charge — — — — — — $0 $0 $20.0m $0
Income (Loss) from Equity Method Investments — ($416k) ($886k) ($1.2m) ($613k) — — — — —
Income Tax Expense (Benefit) — — — — — $1.8m $1.0m $6.0m $1.0m $0
Interest Expense Nonoperating — — — — — — — — $4.0m $8.0m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Payable — ($267k) ($69k) $1.7m $9.3m ($4.8m) $8.0m ($1.0m) $3.0m $24.0m
Debt Securities, Available-for-sale, Realized Gain (Loss) — — — — — $0 — — — —
General and Administrative Expense — $7.6m $13.6m $25.2m $42.4m $72.3m $104.0m $117.0m $120.0m $110.0m
Nonoperating Income (Expense) — $359k $5.3m $4.0m $1.4m $397k $14.0m $39.0m $48.0m $33.0m
Operating Expenses — $54.9m $63.2m $103.7m $201.8m $328.6m $392.0m $457.0m $588.0m $633.0m
Financing Receivable, Credit Loss, Expense (Reversal) — — — — — $0 $0 $0 $0 $0
Net loss ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m)
Stock-based compensation expense $90k $495k $3.9m $9.0m $21.8m $54.5m $65.0m $73.0m $76.0m $60.0m
Noncash lease expense — — — — $1.0m $3.2m $8.0m $8.0m $7.0m $7.0m
Other items, net — — — — — $0 $3.0m $2.0m $0 $1.0m
Receivable from collaboration partners ($6, $14 and $19 from a related party) — — $0 ($132k) ($917k) ($17.0m) $704.0m $15.0m $28.0m $9.0m
Other assets ($—, $6 and ($4) from a related party) ($200k) ($6k) ($80k) ($588k) ($5.4m) $3.3m $2.0m ($14.0m) $22.0m $5.0m
Accounts payable ($24, $—, and $— to a related party) $3.6m ($267k) ($69k) $1.7m $9.3m ($4.8m) $8.0m ($1.0m) $3.0m $24.0m
Deferred revenue (($240), ($56) and ($77) to a related party) — — ($353k) ($2.0m) $178.4m ($367.9m) ($112.0m) ($68.0m) ($56.0m) ($240.0m)
Other liabilities — — — — $10.2m ($498k) $21.0m ($3.0m) $25.0m $8.0m
Purchases of marketable securities — — — — ($740.0m) ($719.0m) ($1.2b) ($788.0m) ($1.0b) ($1.1b)
Proceeds from maturities of marketable securities — — — — $308.0m $690.0m $694.0m $982.0m $929.0m $1.1b
Proceeds from sales of marketable securities — — — — $1.0m $51.0m $143.0m $24.0m $36.0m $71.0m
Payments of employee taxes related to net settlement of equity awards — — — — — — $0 $0 ($7.0m) $0
Beginning Cash Position — — — — — — $151.0m $209.0m $130.0m $153.0m
Cash Flow From Continuing Financing Activities — — — — — — $33.0m $33.0m $277.0m $488.0m
Cash Flow From Continuing Investing Activities — — — — — — ($413.0m) $194.0m ($84.0m) $66.0m
Change In Account Payable — — — — — — $8.0m ($1.0m) $3.0m $24.0m
Change In Other Current Assets — — — — — — $2.0m ($14.0m) $22.0m $5.0m
Change In Other Current Liabilities — — — — — — $21.0m ($3.0m) $25.0m $8.0m
Change In Other Working Capital — — — — — — ($112.0m) ($68.0m) ($56.0m) ($240.0m)
Change In Payable — — — — — — $8.0m ($1.0m) $3.0m $24.0m
Change In Payables And Accrued Expense — — — — — — $8.0m ($1.0m) $3.0m $24.0m
Change In Receivables — — — — — — $704.0m $15.0m $28.0m $9.0m
Change In Working Capital — — — — — — $623.0m ($71.0m) $22.0m ($194.0m)
Changes In Cash — — — — — — $58.0m ($79.0m) $23.0m $72.0m
End Cash Position — — — — — — $209.0m $130.0m $153.0m $225.0m
Financing Cash Flow — — — — — — $33.0m $33.0m $277.0m $488.0m
Free Cash Flow — — — — — — $432.0m ($330.0m) ($176.0m) ($484.0m)
Investing Cash Flow — — — — — — ($413.0m) $194.0m ($84.0m) $66.0m
Issuance Of Capital Stock — — — — — — $0 $25.0m $228.0m $429.0m
Net Intangibles Purchase And Sale — — — — — $0 ($3.0m) $0 — —
Net PPE Purchase And Sale — — — — — — ($6.0m) ($24.0m) ($6.0m) ($2.0m)
Other Non Cash Items — — — — — — $11.0m $10.0m $10.0m $8.0m
Proceeds From Stock Option Exercised — — — — — — $23.0m $8.0m $9.0m $10.0m
Purchase Of Intangibles — — — — — $0 ($6.0m) $0 — —
Purchase Of PPE — — — — — — ($6.0m) ($24.0m) ($6.0m) ($2.0m)
Sale Of Intangibles — — — — — $0 $3.0m $0 — —
Stock Based Compensation — — — — — — $65.0m $73.0m $76.0m $60.0m
Net Cash Provided by (Used in) Operating Activities ($12.9m) ($25.1m) ($43.0m) ($73.5m) $111.2m ($256.2m) $438.0m ($306.0m) ($170.0m) ($482.0m)
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($4.1m) $5.5m $3.7m $1.9m $3.1m $26.1m $6.0m $24.0m $6.0m $2.0m
Payments to Acquire Investments — $96.8m $261.6m $247.8m $739.7m $718.9m — — — —
Net Investment Purchase And Sale — — — — — — ($404.0m) $218.0m ($78.0m) $68.0m
Purchase Of Investment — — — — — — ($1.2b) ($788.0m) ($1.0b) ($1.1b)
Sale Of Investment — — — — — — $837.0m $1.0b $965.0m $1.1b
Payments for (Proceeds from) Other Investing Activities — — — — — — — — $0 —
Net Cash Provided by (Used in) Investing Activities ($38.9m) ($49.1m) ($113.4m) $59.2m ($434.4m) ($3.9m) ($413.0m) $194.0m ($84.0m) $66.0m
Cash flows from financing activities:
Proceeds from debt issuances, net — — — — — — $0 $0 $47.0m $49.0m
Issuance Of Debt — — — — — — $0 $0 $47.0m $49.0m
Long Term Debt Issuance — — — — — — $0 $0 $47.0m $49.0m
Net Issuance Payments Of Debt — — — — — — $0 $0 $47.0m $49.0m
Net Long Term Debt Issuance — — — — — — $0 $0 $47.0m $49.0m
Proceeds from Issuance of Common Stock — — — $1.2m $433.8m $220.2m — $25.0m $228.0m $429.0m
Proceeds from issuance of common stock ($14, $228 and $20 from a related party), net — — $4.1m $1.2m $433.8m $220.2m $0 $25.0m $228.0m $429.0m
Proceeds from issuance of common stock pursuant to equity award plans — — $4.1m $1.2m $5.0m $12.1m $23.0m $8.0m $9.0m $10.0m
Common Stock Issuance — — — — — — $0 $25.0m $228.0m $429.0m
Net Common Stock Issuance — — — — — — $0 $25.0m $228.0m $429.0m
Payments for Repurchase of Common Stock — — — $94k — — — — — —
Net Other Financing Charges — — — — — $5.0m $10.0m — ($7.0m) —
Net Cash Provided by (Used in) Financing Activities $70.1m $107.4m $129.1m $1.1m $438.7m $237.3m $33.0m $33.0m $277.0m $488.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — — ($13.1m) $115.5m ($22.7m) $58.0m ($79.0m) $23.0m $72.0m
Net increase (decrease) in cash, cash equivalents and restricted cash — — ($27.4m) ($13.1m) $115.5m ($22.7m) $58.0m ($79.0m) $23.0m $72.0m
Cash, cash equivalents and restricted cash at beginning of period — — $71.3m $58.1m $173.6m $150.9m $209.0m $130.0m $153.0m $225.0m
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — — — — — — $58.0m ($79.0m) $23.0m $72.0m
Interest Paid, Excluding Capitalized Interest, Operating Activities — — — — — — $0 $0 $1.0m $7.0m
Income Taxes Paid, Net — — — — — $0 $3.0m $5.0m $0 $0

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.